Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888977 | 0.92 | PRMT5 (0.43) | PRMT5GPR119PRCPNPSR1CHEK2 | |
| SCHEMBL889122 | 0.84 | PRMT5 (0.48) | PRMT5GPR119NPSR1CHEK2LMNA | |
| SCHEMBL755564 | 0.83 | AADAT (0.44) | PRMT5GPR119PARP1AADATKLK7 | |
| SCHEMBL888999 | 0.83 | PRMT5 (0.40) | PRMT5GPR119CHEK2KDM4E | |
| SCHEMBL10121392 | 0.82 | PRCP (0.44) | PRMT5AADATPRCP | |
| SCHEMBL16105775 | 0.79 | HPGDS (0.52) | PRCP | |
| SCHEMBL14924575 | 0.78 | ALDH1A1 (0.43) | NPSR1CHEK2KDM4ELMNA | |
| SCHEMBL12104032 | 0.78 | ALDH1A1 (0.43) | NPSR1CHEK2KDM4ELMNA | |
| SCHEMBL12810036 | 0.78 | PRMT5 (0.37) | PRMT5GPR119CHEK2 | |
| SCHEMBL888912 | 0.78 | CYP3A4 (0.35) | PRCPCHEK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | PRMT5 1634/4885GPR119 2170/4885PARP1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.